CURX Company Profile and Key Details

CURX has shown mixed momentum, gaining 3.94% over the past week and -37.33% over the past quarter, though year-to-date performance is up 15.58%. Short-term trend indicators are bullishly aligned (SMA20 4.29%, SMA50 -8.64%, SMA200 -75.24%). The stock’s 14-day RSI is 48.49 (neutral), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.56% below its high and over 20.42% above its low. Average 10-day trading volume of 2.53 million shares is significantly above the 3-month average of 479.14 thousand, indicating heightened recent market interest.

Curanex Pharmaceuticals Inc Common Stock has 27.75 million shares outstanding. The public float is 7.38 million shares, elevated short interest at 0.58% of float. This equals 115.46 thousand shares. The short ratio is 0.03 days. Institutional investors hold 0.0% of the float. Insiders own 69.26%.

Curanex Pharmaceuticals Inc Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.01. This means the shares are trading above this model’s fair value.

Curanex Pharmaceuticals Inc Common Stock (NASDAQ:CURX) closed at $0.32 USD, gaining $0.01 (4.26%) from the previous close of $0.30. The stock is currently mid-range between its 52-week high and low $0.28 and $9.18. With a market capitalization of about $8.94 million, Curanex Pharmaceuticals Inc Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 224.88 thousand shares, trading with heavier-than-usual volume. Headquartered in Jericho, NY, Curanex Pharmaceuticals Inc Common Stock operates in the Healthcare sector and the Biotechnology industry. Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases.

Curanex Pharmaceuticals Inc Common Stock trades at a P/E ratio of -6.34, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.57 suggesting the stock is closer to book value. The P/FCF stands at -0.94, also above market averages.

Our AI price prediction model suggests that Curanex Pharmaceuticals Inc Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.42%, with price expected at $0.27 by March 10, 2026, within a range of $0.25 to $0.29 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 25, 2026, with a range of $0.00 to $0.16. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 24, 2027, within a range of $0.00 to $0.22.

Curanex Pharmaceuticals Inc Common Stock (NASDAQ:CURX) shares are up 15.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Curanex Pharmaceuticals Inc Common Stock trading at a premium to the broader market with a P/E of -6.34. Our AI forecast model points to short-term weakness (-14.42% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.